3. Zyprexa - Top 10 Warnings and Recalls

Drug: Zyprexa

2006 sales: $4.4 billion

Manufacturer: Eli Lilly

Safety concern: Warning; weight gain, metabolic problems

Related Articles:
> Lilly strengthens Zyprexa warnings. Report
> Study: 86% of docs cut Zyprexa use. Report
> Lilly to pay $500M to settle Zyprexa claims. Report
> Lilly ignored Zyprexa safety data on weight, blood sugar. Report
> Lilly accused of promoting off-label Zyprexa use. Report
> NYT accuses Lilly of hiding safety problems. Report

3. Zyprexa - Top 10 Warnings and Recalls

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.